[{"address1": "301 Binney Street", "address2": "3rd Floor", "city": "Cambridge", "state": "MA", "zip": "02142", "country": "United States", "phone": "857 259 3860", "website": "https://scholarrock.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.", "fullTimeEmployees": 150, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jay Thomas Backstrom M.D., M.P.H.", "age": 68, "title": "President, CEO & Director", "yearBorn": 1955, "fiscalYear": 2023, "totalPay": 1071673, "exercisedValue": 0, "unexercisedValue": 3439375}, {"maxAge": 1, "name": "Mr. Edward H. Myles MBA", "age": 51, "title": "CFO, COO & Treasurer", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 720786, "exercisedValue": 0, "unexercisedValue": 857292}, {"maxAge": 1, "name": "Ms. Tracey M. Sacco M.B.A.", "age": 47, "title": "Chief Commercial Officer", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 548855, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mo  Qatanani Ph.D.", "age": 50, "title": "Chief Scientific Officer", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Rushmie  Nofsinger", "title": "Vice President of Corporate Affairs & Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Junlin  Ho J.D.", "age": 44, "title": "General Counsel & Corporate Secretary", "yearBorn": 1979, "fiscalYear": 2023, "totalPay": 563729, "exercisedValue": 0, "unexercisedValue": 112564}, {"maxAge": 1, "name": "Ms. Caryn  Parlavecchio", "age": 51, "title": "Chief Human Resources Officer", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lisa Amaya Price", "title": "Senior Vice President of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Erin  Moore CPA", "age": 48, "title": "Senior Vice President of Finance", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  Iarrobino", "title": "Senior Vice President of Clinical Development & Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 2, "boardRisk": 6, "compensationRisk": 8, "shareHolderRightsRisk": 9, "overallRisk": 7, "governanceEpochDate": 1733011200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 42.09, "open": 41.76, "dayLow": 41.535, "dayHigh": 45.8399, "regularMarketPreviousClose": 42.09, "regularMarketOpen": 41.76, "regularMarketDayLow": 41.535, "regularMarketDayHigh": 45.8399, "beta": 0.478, "forwardPE": -20.101992, "volume": 2884177, "regularMarketVolume": 2884177, "averageVolume": 2116090, "averageVolume10days": 1160130, "averageDailyVolume10Day": 1160130, "bid": 44.62, "ask": 45.07, "bidSize": 500, "askSize": 300, "marketCap": 4192079616, "fiftyTwoWeekLow": 6.76, "fiftyTwoWeekHigh": 46.185, "fiftyDayAverage": 33.4234, "twoHundredDayAverage": 16.9425, "currency": "USD", "enterpriseValue": 4119618560, "floatShares": 69739394, "sharesOutstanding": 93615000, "sharesShort": 14746474, "sharesShortPriorMonth": 15308880, "sharesShortPreviousMonthDate": 1730332800, "dateShortInterest": 1732838400, "sharesPercentSharesOut": 0.1575, "heldPercentInsiders": 0.01074, "heldPercentInstitutions": 0.98477, "shortRatio": 12.52, "shortPercentOfFloat": 0.2915, "impliedSharesOutstanding": 93615000, "bookValue": 0.989, "priceToBook": 45.278057, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -225966000, "trailingEps": -2.36, "forwardEps": -2.15, "enterpriseToEbitda": -18.028, "52WeekChange": 1.3335071, "SandP52WeekChange": 0.2421279, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "SRRK", "underlyingSymbol": "SRRK", "shortName": "Scholar Rock Holding Corporatio", "longName": "Scholar Rock Holding Corporation", "firstTradeDateEpochUtc": 1527255000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "d4172360-ba22-3374-b294-8dd0e33412b6", "messageBoardId": "finmb_548810128", "gmtOffSetMilliseconds": -18000000, "currentPrice": 44.78, "targetHighPrice": 57.0, "targetLowPrice": 33.0, "targetMeanPrice": 46.375, "targetMedianPrice": 48.5, "recommendationMean": 1.44444, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 8, "totalCash": 139064992, "totalCashPerShare": 1.485, "ebitda": -228515008, "totalDebt": 66606000, "quickRatio": 3.561, "currentRatio": 3.884, "debtToEquity": 84.103, "returnOnAssets": -0.671, "returnOnEquity": -1.8307099, "freeCashflow": -102019128, "operatingCashflow": -188784992, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-12-21"}]